Search Results

Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical Trials.

• Authors : Shah, Neil J.; Della Pia, Alexandra; Wu, Tianmin

Subjects: PATIENT safety; CLINICAL trials; SMOKINGUNITED States

• Source: Cancers; Jun2024, Vol. 16 Issue 12, p2223, 16p

Record details

Solriamfetol improves driving performance in patients with excessive sleepiness.

Subjects: *DRUG efficacy; *PHENYLALANINE; *HYPERSOMNIANETHERLANDS

• Source: Brown University Psychopharmacology Update. Sep2022, Vol. 33 Issue 9, p4-5. 2p.

Record details

Risks and benefits associated with the primary functions of artificial intelligence powered autoinjectors.

• Authors : Machal, Marlon Luca

Subjects: MULTIPLE sclerosis treatment; TREATMENT of diabetes; RHEUMATOID arthritis treatmentUNITED States; UNITED KingdomUNITED States. Food & Drug Administration

• Source: Frontiers in Medical Technology; 2024, p1-9, 9p

Record details

Tularemia Clinical Manifestations, Antimicrobial Treatment, and Outcomes: An Analysis of US Surveillance Data, 2006–2021.

• Authors : Wu, Hung-Jen; Bostic, Taylor D; Horiuchi, Kalanthe

Subjects: PUBLIC health surveillance; DRUG efficacy; TULAREMIAUNITED States

• Source: Clinical Infectious Diseases; 2024 Supplement, Vol. 78, pS29-S37, 9p

Record details

Paxlovid for nonhospitalized patients with COVID‐19.

• Authors : Johari, Fatima; Verma, Rajesh

Subjects: THERAPEUTIC use of protease inhibitors; COMBINATION drug therapy; RISK assessmentUNITED StatesUNITED States. Food & Drug Administration

• Source: Academic Emergency Medicine; Jun2024, Vol. 31 Issue 6, p621-623, 3p

Record details

Pharmaceutical messianism and the politics of COVID-19 in the United States.

• Authors : Lasco, Gideon; Yu, Vincen Gregory; Bharti, Nishtha

Subjects: THERAPEUTIC use of monoclonal antibodies; HYDROXYCHLOROQUINE; INTELLECTFLORIDA; UTAH; TEXAS

• Source: Global Public Health; Jan2024, Vol. 19 Issue 1, p1-15, 15p

Record details

The Direct and Long-Term Effects of Raloxifene as Adjunctive Treatment for Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Clinical Trial.

• Authors : Brand, Bodyl A; Boer, Janna N de; Marcelis, Machteld C

Subjects: DRUG therapy for schizophrenia; DRUG efficacy; RESEARCHNETHERLANDS; BELGIUM

• Source: Schizophrenia Bulletin; Nov2023, Vol. 49 Issue 6, p1579-1590, 12p

Record details

Reaction mixed over FDA committee rejection of MDMA therapy for PTSD.

• Authors : Canady, Valerie A.

Subjects: DRUG approval laws; POST-traumatic stress disorder; PSYCHOTHERAPYUNITED StatesUNITED States. Food & Drug Administration

• Source: Mental Health Weekly; Jun2024, Vol. 34 Issue 24, p1-3, 3p

Record details

A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month Findings.

• Authors : Botson, John K.; Saag, Kenneth; Peterson, Jeff

Subjects: DRUG efficacy; RESEARCH; LIVER function testsUNITED States

• Source: ACR Open Rheumatology; Aug2023, Vol. 5 Issue 8, p407-418, 12p

Record details

Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records.

• Authors : Polito, Letizia; Jinjoo Shim; Hurvitz, Sara A.

Subjects: THERAPEUTIC use of monoclonal antibodies; THERAPEUTIC use of antineoplastic agents; DRUG efficacyUNITED States

• Source: JCO Oncology Practice; Jul2023, Vol. 19 Issue 7, p435-445, 25p

Record details